Catalyst Funds Management Pty Ltd Increases Holdings in Enhabit, Inc. (NYSE:EHAB)

Catalyst Funds Management Pty Ltd boosted its stake in shares of Enhabit, Inc. (NYSE:EHAB) by 34.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,100 shares of the company’s stock after buying an additional 9,700 shares during the period. Catalyst Funds Management Pty Ltd’s holdings in Enhabit were worth $298,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. FMR LLC boosted its position in shares of Enhabit by 138.4% during the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after acquiring an additional 1,967 shares during the last quarter. Gladius Capital Management LP raised its stake in Enhabit by 78.2% during the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after purchasing an additional 2,747 shares during the period. Intech Investment Management LLC acquired a new position in Enhabit in the 3rd quarter valued at about $96,000. Versor Investments LP purchased a new stake in shares of Enhabit in the 3rd quarter valued at approximately $97,000. Finally, Stoneridge Investment Partners LLC increased its holdings in shares of Enhabit by 22.6% during the 4th quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company’s stock worth $98,000 after buying an additional 2,308 shares during the last quarter.

Enhabit Stock Up 0.8 %

Enhabit stock opened at $8.58 on Friday. The company has a market capitalization of $432.87 million, a PE ratio of -3.70 and a beta of 1.80. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. Enhabit, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The firm has a 50 day moving average price of $8.28 and a 200 day moving average price of $7.92.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Leerink Partners reiterated a “market perform” rating and issued a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group reiterated a “buy” rating on shares of Enhabit in a report on Thursday, March 6th.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.